COMMON GENITAL COLONIZATION / CARE & TRANSMISSION
U. parvum and U. urealyticum
Ureaplasma frequently lives in the genital tract without causing disease. A positive PCR is not automatically an STI diagnosis, a reason for antibiotics or evidence of a recent transmission. In a healthy adult without relevant symptoms, the usual evidence-based approach is not to pursue eradication. [08][09][10]
Transmission risk
Risk by type of contact
Bottom line. For Ureaplasma, the central uncertainty is both how often acquisition occurs and whether detected carriage causes disease. Routine eradication or partner treatment is not justified by a positive result alone.
General
Oral
Vaginal
Anal
Kissing
What changes the risk (3)
- Colonization versus disease. LOW for transmission quantification: common carriage, species differences and possible high-load U. urealyticum urethritis make the endpoint crucial. A positive test alone is not proof of causation or recent acquisition. Sources 1
- Antibiotics. LOW: no evidence-based percentage for treating asymptomatic carriers to prevent disease in partners. European guidance discourages routine screening and treatment. Sources 1
- Other modifiers. LOW: no validated act-specific multipliers for ejaculation, menstruation, circumcision, vaccination or co-infection; no established vaccine/PrEP/PEP regimen for routine prevention. Sources 1
Condoms and dental dams
No organism-specific clinical condom/dental-dam effectiveness estimate identified. Do not present a generic bacterial-STI figure as Ureaplasma evidence. Evidence: Low Sources 1
Sources for this risk profile (1)
- Horner P, Donders G, Cusini M, Gomberg M, Jensen JS, Unemo M Journal of the European Academy of Dermatology and Venereology, 2018. Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women? A position statement from the European STI Guidelines Editorial Board. DOI: 10.1111/jdv.15146. pubmed.ncbi.nlm.nih.gov
* How to read these figures. Each is a published estimate under the conditions shown beside it, usually an untreated partner and a single act or partnership. It is not a prediction of your personal risk.
- Evidence: High
- Several prospective studies or a systematic review broadly agree.
- Evidence: Medium
- One or two studies, wide uncertainty, or a model.
- Evidence: Low
- Guideline judgment, case reports, or extrapolation.
Where no risk level is shown, the evidence cannot rank it. That is not the same as low.
Evidence reviewed through 2026-10-27. For reference only; not medical advice.
When to test after a possible exposure
No validated routine post-exposure testing window; routine testing is generally not recommended.
When to be seen sooner. Symptoms that persist are worth assessing for well-established causes, rather than repeating broad panels without a clinical reason.
-
Species-specific NAAT / quantitative testing only for a defined clinical question
No established exposure-to-test rule-out interval.
Do not schedule a universal screening test solely because a partner has carriage detected.
Specimens: Clinician-selected genital specimen
Sources 1
Early negatives, after treatment, and screening limits
An early negative result. A negative early test cannot define acquisition timing; a positive test cannot establish when, from whom, or whether disease-causing infection was acquired.
After treatment. No routine eradication or partner test-of-cure schedule is established for asymptomatic carriage.
Screening limits. European guidance discourages routine testing/treatment of U. parvum, U. urealyticum and M. hominis. Selected high-load U. urealyticum urethritis evaluation is not a general screening program.
Kissing and body sites. No validated post-kissing, throat or rectal screening window is established.
Sources for testing guidance (1)
- Horner P et al., JEADV / European STI Guidelines Editorial Board. Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum?. 2018. DOI: 10.1111/jdv.15146. onlinelibrary.wiley.com
Treatment
An isolated positive result on a broad panel is not a reason to take antibiotics on your own. European guidance discourages routine testing and treatment in adults with or without symptoms; symptoms are first checked for well-established causes. A specialist may look at high-load U. urealyticum in selected persistent urethritis. Species, clinical context and other diagnoses matter. [08][09][10]
Actions
1. Interpret the result. Ask which species was detected and whether it explains the clinical problem. U. parvum is often colonization; U. urealyticum can also be carried without illness. A laboratory detection threshold is not a disease threshold. [08][09]
2. No testing cascade is needed. There is no standard partner lookback, routine partner treatment, throat-screening program or repeat test-to-clear for uncomplicated carriage. A positive result does not need to become antibiotics for a whole network. [08][09]
3. Look after symptoms that persist. Ongoing urinary or genital symptoms are worth care even when Ureaplasma is incidental. Pregnancy complications, newborn illness and major immune suppression are separate specialist situations, and do not mean routine adult carriage is dangerous. [08][09][10]
SCIENCE & CONTEXT
Ureaplasma / the evidence
History
Small genital organisms initially called T-strain mycoplasmas were reported in 1954. Their ability to break down urea informed the later Ureaplasma classification. In 2002, the former biovars were formally separated into U. parvum and U. urealyticum. More sensitive molecular panels made detection easier; evidence about clinical benefit has not supported treating every detection. [08][11][12]
Impact
Colonization means that an organism is present without established disease. Ureaplasma lacks a cell wall and may be part of a person's genital microbial community. In selected men with urethritis, high-load U. urealyticum may contribute after other causes have been excluded. CDC does not identify an established role for either Ureaplasma species in cervicitis. [08][09][10]
The related bacterium Mycoplasma hominis is also not interchangeable with Mgen. Routine screening or treatment of M. hominis is similarly discouraged in the European position statement. A generic label such as "mycoplasma positive" is insufficient: the species must be clear. [08]
Probability at a glance
Chance that at least one recent partner carries Ureaplasma, by number of partners in six months. Carriage is common and is not disease.
| Partners | 40% carriage | 50% carriage |
|---|---|---|
1-2 | 40.0–64.0 | 50.0–75.0 |
3-5 | 78.4–92.2 | 87.5–96.9 |
6-10 | 95.3–99.4 | 98.4–>99.9 |
11-20 | 99.6–>99.9 | >99.9 |
Probability that at least one partner carries Ureaplasma under 40% or 50% carriage scenarios. These are colonization scenarios, not disease or acquisition probabilities. SSI describes roughly 40% carriage in healthy men and 40-50% in healthy women. [09]
High carriage makes encountering this organism unsurprising. It does not make symptoms unimportant, nor does it justify antibiotics in everyone. See the clinical distinctions in Ureaplasma: presence is not disease.